Company Analysis

Actinium Pharmaceuticals, Inc (ATNM)

NYSE: ATNM · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Grade4.3
◀ Past 3.5● Present 3.7▶ Future 5.2
1 est.

Who runs Actinium Pharmaceuticals, Inc

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Seth Sandesh
Chief Executive Officer. First filing Jan 2013, latest Sep 4, 2026, 8 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
17 people on the record since 2013
Officerssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
David Matthew TChief Financial OfficerOct 2026Oct 16, 2026none
Heeger Steffen WilhemChief Medical OfficerSep 2026Sep 10, 2026none
Kamal AdeelaChief Scientific OfficerSep 2026Sep 10, 2026none
Seth SandeshChief Executive OfficerJan 2013Sep 4, 2026none
Directorssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameRoleFirst filingLatest filingSales, 12 months
Almenoff June SheriedirectorNov 2024Sep 4, 2026none
Chell Jeffrey W.directorMay 2018Sep 4, 2026none
Nicholson, C. DaviddirectorMar 2015Sep 4, 2026none
Shetty AjitdirectorMar 2017Sep 4, 2026none
Steinhart Richard IdirectorNov 2013Sep 4, 2026none
Earlier names on the record9, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ATNM · research, not advice